Gland Pharma Ltd

Gland Pharma Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.

Gland Pharma Investor Presentation: Key Takeaways

Gland Pharma reported strong Q1FY27 results with 20% revenue growth and 47% PAT growth. Management highlighted a major strategic CDMO contract and raised long-term CAGR outlook to 20% following recent business wins.

Call

Guides 15% growth

Gland Pharma Earnings Call Transcript: Key Takeaways

Gland Pharma reports a strong start to FY27, driven by CDMO and B2B growth, though currency shifts significantly impacted the bottom line compared to the previous quarter.

Call

Guides 15% growth

Gland Pharma Investor Presentation: Key Takeaways

Gland Pharma reported Q1FY27 revenue of ₹18,003 Mn (20% YoY) with PAT of ₹3,170 Mn (47% YoY). Growth was driven by CDMO product launches and B2B volume expansion in US and Europe.

Gland Pharma Earnings Call: Key Takeaways

Gland Pharma reported record quarterly revenue of INR 17,428M (+22% YoY) for Q4FY26, driven by CDMO growth and the Cenexi turnaround. FY26 adjusted PAT reached INR 10,455M with a 16% margin.

Gland Pharma Earnings Call: Key Takeaways

Gland Pharma reports a recovery quarter with consolidated revenue up 7% and a sharp 39% EBITDA jump, primarily driven by Cenexi reaching EBITDA break-even and lower raw material costs.

Gland Pharma Earnings Call: Key Takeaways

Gland Pharma reports strong FY26 performance with 14% revenue growth and 50% Adj. PAT growth, driven by US market gains and Cenexi recovery.